A cd19-based chimeric antigen receptor and application thereof
AssigneeBeijing Meikang Geno-Immune Biotechnology Co., Ltd.
InventorRui Zhang
Life of this patent
Estimating the term…
Abstract
The present application provides a chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an antigen-binding domain, a transmembrane domain, a costimulatory signal transduction region, a CD3ζ signal transduction domain, and an inducible suicide fusion domain in tandem arrangement; wherein the antigen-binding domain binds to a tumor surface antigen and the tumor surface antigen is CD19.
Claims23
A CD19-based chimeric antigen receptor comprising an antigen-binding domain, a transmembrane domain, a costimulatory signal transduction region, a CD3ζ signal transduction domain, and an inducible suicide fusion domain in tandem arrangement;
- wherein the antigen-binding domain binds to a tumor surface antigen, the antigen-binding domain is a single chain antibody against the tumor surface antigen CD19, the costimulatory signal transduction region comprises a CD27 signal transduction domain, and the inducible suicide fusion domain is iCasp9.
(canceled)
Dependencies are inferred from the claim text.